AUROPHARMA / Q3-FY25 / claim-ledger

Audit the questions that mattered.

Aurobindo Pharma · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ3-FY25 · 2025-02-12Back to quarter ↗

Questions audited

4

Answered directly

38%

Numeric claims

0

Consistency

—

Question ledger

What was answered, and how?

Shyam Steele · Research desk

partial

Potential US tariffs on pharma and mitigation strategies

As yet, we don't know what's the final outcome. We don't know what the tariff is. There's a lot of noise right now. We would continue to import from India. We have built up good infrastructure in the U.S. We have a data plan that's coming up. And we also have the Puerto Rico plan.

Shyam Steele · Research desk

partial

ROCE on US investments vs corporate averages

The units like Penicillin or Eugia or China, these are all in the ramping up and then incurring losses. Once the full ramp-up is taking place, you see it will get converted into positive, which will help us to improve the ROCE.

Vivek Agarwal · Research desk

partial

Sustainability of gross margins at 58-59%

Already all these products, PenG and other things should start contributing, which will help to retain the gross margin certainly.

Vivek Agarwal · Research desk

declined

Can gross margins move up meaningfully?

I think let's park this question for the next call.